Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. - Wikidata - awgldk - TriplyDB

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.

http://www.wikidata.org/entity/Q46502896

about

Nelarabine in the treatment of refractory T-cell malignancies Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.Childhood acute lymphoblastic leukemia: Integrating genomics into therapy Chimeric antigen receptor T cells for sustained remissions in leukemia Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434 Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients Nelarabine in the treatment of refractory T-cell malignant diseases.Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Treatment of pediatric acute lymphoblastic leukemia.Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder.Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy.Advances in paediatric cancer treatment Update on the therapy of highly aggressive non-Hodgkin's lymphoma.Nelarabine: efficacy in the treatment of clinical malignancies.Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.Clofarabine for the treatment of acute lymphoblastic leukemia.Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia.Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin.Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Adult acute lymphoblastic leukemia: concepts and strategies.Educational paper. The development of new therapies for pediatric oncology.New nucleoside analogs for patients with hematological malignancies.New drug therapies in peripheral T-cell lymphoma.Treatment algorithms for mature T-cell and natural killer-cell neoplasms.Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.

P2860

Q24569660-67EFDB01-E8D4-48B1-B853-20592E5B5D7C Q24633723-623DA6B4-7B31-4D87-8056-6C8BEF9B209D Q26746934-0B7F5634-CB82-4438-B272-1BE95F2CA9DB Q26781328-B4BB3210-C316-4B33-BC9E-628BDE668002 Q27852067-74B51780-6C5F-4873-9360-12AB4E4619A4 Q28080463-0D9F6348-949F-4FB2-B9C6-7A1C456A9E05 Q29617588-11C8AA6E-E290-459C-BEB1-C3046B1E7886 Q30240892-4FC2A2C8-8AFF-4992-AB50-A70DEB832726 Q30243925-A8B0091E-E5C8-4F9B-B2E3-ED19141F89B3 Q30300395-FFFB2EB0-2745-4D82-B9F0-8F8E2DCE8F79 Q30417943-A275C75A-4C7D-4D93-A525-17B83B40F8E9 Q33374461-62D5876F-7A36-485A-8B11-EF0712FFC192 Q33711119-FDABA7C9-F25B-4596-9485-527DEECF51A5 Q33916091-64D21B32-6F96-4FCD-BE0A-AF1B36D7BBBE Q34469099-4BA076B2-85D5-4998-A3B3-3844BD43D69C Q34559575-11D5BEE8-0812-436E-9C75-6199270E91D9 Q34592646-8F4426A3-385E-4D08-8415-FFF96CFB7A1D Q34764504-4EDBE1D1-D632-4168-8E69-6B8B4380F15A Q35196702-4F184552-D24D-40F3-A91D-FEA536EFDE98 Q35615374-B3C6BBEB-FDBB-47D8-858B-29A929586C5F Q35667279-5B06B9D8-9A6A-4964-8402-CBBD58FE73E9 Q35989408-F9A85DB4-C887-44AA-AB1E-95BC46F0A801 Q36508149-089A9B95-361E-4CE0-9BBD-9465E7742CF9 Q36508630-80F89119-49B2-49DC-B48F-5968DF279D2B Q36521840-7F79F661-0EFA-408D-8B32-73D5BB8F38D1 Q36572507-EA074380-D7C1-43F7-A584-949616C54A24 Q36654341-77A3B3A2-3416-416D-B056-C39D7AC8A3E0 Q36731404-F9C8AB22-2D57-487D-A805-43F48E55CE6C Q36758604-EA146BBA-F399-44A0-83E1-A7A813B6CED6 Q36771221-D256658E-2063-4F16-89E1-9AA51793B2B7 Q37048013-EA11D207-5C54-424A-8CE6-080EE090FBFD Q37271941-D3EFC10B-4872-44BB-9E7C-1EF7F407C79B Q37360025-BA7D329B-4EF1-406D-8D83-64C0E0519E37 Q37424784-96C4B021-B6F1-4B77-BC01-E13B63A636FC Q37681450-9F99830E-3A55-4887-B550-52BAECD6852E Q37824438-1702DA1B-FA6D-4DBA-B263-A1F04595E17B Q37841589-0B0DFDEA-BF70-477F-8354-C1BC7C6E3243 Q37854715-16592E22-F23A-4CF9-8770-2451625FBA98 Q37932546-3F5DE602-0D53-4E30-8822-22ADCFF27BCB Q38033592-01E3D87D-9CF8-4A54-82FA-B5C0F53AB6E6

P2860

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.

http://www.wikidata.org/entity/Q46502896

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Phase II study of nelarabine ( ...... the Children's Oncology Group.

@en

Phase II study of nelarabine

@nl

type

label

Phase II study of nelarabine ( ...... the Children's Oncology Group.

@en

Phase II study of nelarabine

@nl

prefLabel

Phase II study of nelarabine ( ...... the Children's Oncology Group.

@en

Phase II study of nelarabine

@nl

P1433

Q46502896-38B08F7C-45AF-4438-9928-868C897B0725

P1476

Q46502896-2FFE8824-4640-4D10-A8F7-47C37CAB3780

P2093

Q46502896-05A251BA-4691-4C4A-B3AF-946A818D7964

Q46502896-293DF526-554B-4277-A76D-5C0ABB6824EF

Q46502896-3C70E63E-6E52-4E1F-8CE2-592959EBF05E

Q46502896-4370AA19-C3CB-4665-B744-9DD754F91A82

Q46502896-4D4FC5D2-8F80-41C3-97E0-6057B5D162A6

Q46502896-651FFF95-EE65-4C3B-BF12-349AE8C86DB4

Q46502896-77ADE72D-54D7-40C2-8CC5-FD84307EAB2F

Q46502896-A00ED55E-8D9B-482E-A363-6130EA2519A9

Q46502896-B43D3096-A032-413B-A705-58E31E2A1101

Q46502896-BCB32837-FCEE-434C-BEAB-B765EE5B0A73

P304

Q46502896-14A5021C-D74E-4A53-8E5F-53E82C786B55

P31

Q46502896-54BAD11E-5DB9-417B-BB0F-8FD2A1C519F0

P356

Q46502896-0A527007-7EB2-4504-AFCB-EABCC8AD075A

P407

Q46502896-21D50D9C-144C-40EC-ABF2-4E806D2F510F

P433

Q46502896-D1143880-5211-49A9-8007-FED633B200D6

P478

Q46502896-D3DDC7F1-BDF4-4FC6-A4AB-CD2D872A3EAB

P50

Q46502896-2D4E0568-02E8-4A4D-9AE1-A6CF2A51568B

Q46502896-F50D2EB8-7118-4414-A2FF-43DA4E9AFAD3

P577

Q46502896-48C3C2CE-E892-4AFE-B1E9-2B246830CC27

P698

Q46502896-5E9F5537-DCA7-4E77-8B36-4D68B7300458

P356

JCO.2005.03.426

P1433

Journal of Clinical Oncology

P1476

Phase II study of nelarabine ( ...... the Children's Oncology Group.

@en

P2093

Amy Billett

http://www.w3.org/2001/XMLSchema#string

Anthony Murgo

http://www.w3.org/2001/XMLSchema#string

Children's Oncology Group

http://www.w3.org/2001/XMLSchema#string

Greg Reaman

http://www.w3.org/2001/XMLSchema#string

James Whitlock

http://www.w3.org/2001/XMLSchema#string

Joanne Kurtzberg

http://www.w3.org/2001/XMLSchema#string

Mark Bernstein

http://www.w3.org/2001/XMLSchema#string

Mark Krailo

http://www.w3.org/2001/XMLSchema#string

Meenakshi Devidas

http://www.w3.org/2001/XMLSchema#string

Michael B Harris

http://www.w3.org/2001/XMLSchema#string

P304

3376-3382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.03.426

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15908649

http://www.w3.org/2001/XMLSchema#string